VA
PYXS icon

Verdad Advisers’s Pyxis Oncology PYXS Stock Holding History

Verdad Advisers’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$135K Buy
+44,899
New +$85.9K 0.13% 173

Other funds holding PYXS

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Verdad Advisers's PYXS Position: Q2 2026 in Review

Verdad Advisers opened a new position in Pyxis Oncology (PYXS) in Q2 2026: 44,899 shares worth $135K. The stake represents 0.13% of the portfolio and ranks #173 among its holdings.

76 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

  • Verdad Advisers held 44,899 shares of Pyxis Oncology worth $135K as of Q2 2026.
  • Pyxis Oncology was a new Verdad Advisers position in Q2 2026.
  • Pyxis Oncology made up 0.13% of Verdad Advisers's portfolio in Q2 2026, its #173 holding.
  • 76 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.